Richard Schlenk

22PUBLICATIONS
163CO-AUTHORS
NanomedicineImmunogenetics (incl. genetic immunology)Molecular targetsQuantum optics and quantum optomechanicsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Aug 03, 2026
Author Correction: IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.

|Jul 01, 2026
IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.

|Apr 09, 2026
Multi-layered molecular profiling informs the diagnosis and targeted therapy of desmoplastic small round cell tumor.

Marcus Renner, Małgorzata Oleś, Nagarajan Paramasivam

|Apr 08, 2026
Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First.

Mark J Levis, Harry P Erba, Pau Montesinos

|Oct 06, 2025
FLT3-ITD measurable residual disease from the QuANTUM-First trial.

Mark J Levis, Harry P Erba, Pau Montesinos

|Sep 30, 2024
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin.

Frank G Rücker, Lars Bullinger, Sibylle Cocciardi

Pageof 4

Frequent Collaborators

5 joint publications

Carsten Müller-Tidow

4 joint publications

Maria Teresa Voso

3 joint publications

Helmut Salih

3 joint publications

Richard Larson